Download PDF
Thromb Haemost 1985; 54(02): 394-396
DOI: 10.1055/s-0038-1657747
Original Article
Schattauer GmbH Stuttgart

Plasma Levels of Platelet and Vascular Prostaglandin Derivatives in Children with Sickle Cell Anaemia

George R Buchanan
The Department of Pediatrics, The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, TX, USA
,
Christine A Holtkamp
The Department of Pediatrics, The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, TX, USA
› Author Affiliations
Further Information

Publication History

Received 02 August 1984

Accepted 22 April 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Platelet and vascular endothelial prostaglandin derivatives were measured by radioimmunoassay in the plasma of 39 children with homozygous sickle cell anaemia and 27 control subjects. The levels of both thromboxane B2 and 6-keto-PGF1α, the stable endproducts of platelet and vascular prostaglandin metabolism, were significantly (p <0.001) greater in sickle cell anaemia plasma than in the plasma of the controls. There were no differences in levels of either 6-keto-PGF1α or thromboxane B2 between steady state and vaso-occlusive crisis in the sickle cell patients. Injury to the endothelial lining of blood vessels may occur in sickle cell anaemia as a consequence of contact with the abnormal erythrocytes.

Keywords

Sickle cell anaemia - Platelets - Prostaglandin - Thromboxane - Prostacyclin
 

  • References

  • 1 Gruppo RA, Glueck HI, Granger SM, Miller MA. Platelet function in sickle cell anaemia. Thromb Res 1977; 10: 325-335
    CrossrefPubMedGoogle Scholar
  • 2 Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973; 82: 44-53
    PubMedGoogle Scholar
  • 3 Ritter JM, Blair IA, Barrow SE, Dollery CT. Release of prostacyclin in vivo and its role in man. Lancet 1983; 01: 317-319
    PubMedGoogle Scholar
  • 4 Majerus PW. Arachidonate metabolism in vascular disorders. J clin Invest 1983; 72: 1521-1525
    CrossrefPubMedGoogle Scholar
  • 5 Bunting S, Moncada S, Vane JR. The prostacyclin-thromboxane A02 balance: pathophysiological and therapeutic implications. Br Med Bull 1973; 39: 271-276
    PubMedGoogle Scholar
  • 6 Mehta P, Albiol L. Prostacyclin and platelet aggregation in sickle cell disease. Pediatrics 1982; 70: 354-356
    PubMedGoogle Scholar
  • 7 Mehta P. Increased plasma thromboxane levels in sickle cell disease. Pediatr Res 1981; 15: 582
    PubMedGoogle Scholar
  • 8 Mankad VN, Longenecker G. Platelet and endothelial prostanoids in sickle cell disease. Pediatr Res 1983; 17: 237A (Abstr)
    CrossrefPubMedGoogle Scholar
  • 9 Stuart MJ, Sills RH. Deficiency of plasma prostacyclin or PGI02 regenerating ability in sickle cell anaemia. Br J Haematol 1981; 48: 545-550
    CrossrefPubMedGoogle Scholar
  • 10 Salmon JA. Measurement of eicosanoids by bioassay and radioimmunoassay. Br Med Bull 1983; 39: 227-231
    CrossrefPubMedGoogle Scholar
  • 11 Zar JH. Biostatistical Analysis. Englewood Cliffs N J: Prentice-Hall, Inc.; 1974: 152-154
    Google Scholar
  • 12 Greaves M, Preston FE. Plasma 6-keto-prostaglandin F1α: fact or fiction. Thromb Res 1982; 26: 145-157
    CrossrefPubMedGoogle Scholar
  • 13 Belch JJF, Greer I, McLaren M. et al. Measurement of prostacyclin metabolites. Lancet 1983; 02: 1504
    PubMedGoogle Scholar
  • 14 Butt RW, Buchanan MR. Basal 6-keto-PGF1α levels: influence of sampling techniques. Thromb Res 1983; 29: 469-470
    CrossrefPubMedGoogle Scholar
  • 15 Ditter H, Heinrich D, Matthias FR. et al. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of β-thromboglobulin, platelet factor 4, thromboxane B02, 6-keto-prostaglandin F1α, and heparin. Thromb Res 1983; 32: 393-408
    CrossrefPubMedGoogle Scholar
  • 16 Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anaemia. N Engl J Med 1972; 287: 846-849
    CrossrefPubMedGoogle Scholar
  • 17 Buchanan GR, Holtkamp CA. Platelet aggregation, malondial-dehyde generation and production time in children with sickle cell anaemia. Thromb Haemostas 1981; 46: 690-693
    PubMedGoogle Scholar
  • 18 Buchanan GR, Holtkamp CA. Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol 1983; 54: 595-603
    CrossrefPubMedGoogle Scholar
  • 19 Greenberg J, Ohene-Frempong K, Halus J. et al. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 1983; 102: 781-784
    CrossrefPubMedGoogle Scholar
  • 20 Richardson SGN, Matthews KB, Stuart J. et al. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979; 41: 95-103
    CrossrefPubMedGoogle Scholar
  • 21 Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 1980; 33: 622-625
    CrossrefPubMedGoogle Scholar
  • 22 Hebbel RP, Yamada O, Moldow CF. et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium. Possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 1980; 65: 154-160
    CrossrefPubMedGoogle Scholar
  • 23 Mackie I, Bull H, Brozovic M. Altered factor VIII complexes in sickle cell disease. Br J Haematol 1980; 46: 499
    CrossrefPubMedGoogle Scholar
  • 24 Sarji KE, Eurenius K, Fullwood CO, Schraibman HB, Colwell JA. Abnormalities of platelet aggregation in sickle cell anemia. Presence of a plasma factor inhibiting aggregation by ristocetin. Thromb Res 1979; 14: 283
    CrossrefPubMedGoogle Scholar